Sinovac Biotech Ltd.
No.39 Shangdi Xi Rd
Haidian District
Beijing
100085
China
Tel: 86-10-82890088
Fax: 86-10-62966910
Website: http://www.sinovac.com/
Email: sinovac@sinovac.com
422 articles about Sinovac Biotech Ltd.
-
Sinovac Amends Shareholder Rights Plan - February 21, 2024
2/21/2024
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that its board of directors has amended its shareholder rights plan.
-
Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer - January 18, 2024
1/18/2024
Sinovac Biotech Ltd. announced today that its Board of Directors (the “Board of Directors”) unanimously determined that the partial tender offer (the “Tender Offer”) by Alternative Liquidity Index LP (“Alternative Liquidity”).
-
SINOVAC Reports on the Clinical Trial Progress of its Anti-COVID-19 Antibody SA55 Injection
9/11/2023
Sinovac Biotech Ltd. announced that the Company has completed the phase I clinical trial for its broad-spectrum neutralizing antibody product, the Anti-COVID-19 Antibody SA55 Injection in Beijing and has entered the phase II clinical trial in Shanghai after successfully enrolling its first participant recently.
-
Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer
9/5/2023
Sinovac Biotech Ltd. announced that its Board of Directors unanimously determined that the partial tender offer by Alternative Liquidity Index LP to acquire up to 10,000,000 common shares of Sinovac for $0.03 per share in cash is NOT advisable and is NOT in the best interests of the Company or its shareholders.
-
Sinovac Confirms Receipt of an Unsolicited Partial Tender Offer - August 29, 2023
8/29/2023
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, confirmed that it is aware of an unsolicited partial tender offer from Alternative Liquidity Index LP to purchase up to a maximum of 10,000,000 shares of the Company, representing approximately 10.05% of the Company’s outstanding shares, for $0.03 per share in cash.
-
SINOVAC Reports Unaudited First Half of 2023 Financial Results
8/15/2023
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced its unaudited financial results for the six months ended June 30, 2023.
-
SINOVAC’s CoronaVac® Answers Hong Kong’s Need for Self-Pay COVID-19 Vaccines
5/10/2023
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced it will provide its inactivated COVID-19 vaccine, CoronaVac®, to self-paying groups in Hong Kong.
-
SINOVAC Reports Unaudited Second Half of 2022 Financial Results and Files 2022 Annual Report on Form 20-F
5/1/2023
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, has filed its 2022 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2022.
-
Sinovac Amends Shareholder Rights Plan - February 22, 2023
2/22/2023
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that its board of directors has amended its shareholder rights plan.
-
SINOVAC Reports Unaudited First Half of 2022 Financial Results
12/29/2022
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced its unaudited financial results for the six months ended June 30, 2022.
-
SINOVAC Varicella Vaccine Prequalified by WHO
11/4/2022
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that it received prequalification from the World Health Organization for its live attenuated varicella vaccine on November 3, 2022.
-
SINOVAC to Showcase Products at CPHI Frankfurt
10/28/2022
Sinovac Biotech Ltd. announced that the Company will participate in CPHI Frankfurt, one of the world’s largest pharmaceutical exhibitions, from 1st to 3rd of November, in Frankfurt, Germany.
-
SINOVAC Approved to Initiate Clinical Trial for Its Omicron Containing COVID-19 Vaccine in Chile
9/6/2022
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that the Chilean Public Health Institute approved a phase II clinical trial for its inactivated Omicron strain COVID-19 vaccine and trivalent COVID-19 vaccine on August 31st.
-
SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong
8/3/2022
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that based on related clinical trials and studies of vaccination for local children and adolescents, the Health Bureau of the Government of the Hong Kong Special Administrative Region of the People’s Republic of China has approved the Company’s COVID-19 vaccine, intended for children aged 6 months to 3 years.
-
SINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile
7/19/2022
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that a phase III clinical trial for SINOVAC’s inactivated quadrivalent influenza vaccine was initiated in the Republic of Chile through a collaboration with the Pontificia Universidad Católica de Chile.
-
SINOVAC COVID-19 Vaccine Is Authorized for Emergency Use in Kids Aged 3-5 In Brazil
7/14/2022
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that its COVID-19 vaccine has been approved by the Brazilian Health Regulatory Agency for emergency use in children from 3 to 5 years old on 13 July.
-
SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa
6/25/2022
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that the South African Health Products Regulatory Authority granted conditional registration to SINOVAC CoronaVac® in aged 18 and above adults, based on acceptable safety, quality, and efficacy data submitted.
-
SINOVAC Polio Vaccine Prequalified by WHO
6/9/2022
SINOVAC Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that it received the World Health Organization prequalification for its Poliomyelitis Vaccine on June 2, 2022.
-
SINOVAC Updates the Status Under Holding Foreign Companies Accountable Act
5/6/2022
Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, is aware that the Company has been identified by the United States Securities and Exchange Commission (“SEC”) under the Holding Foreign Companies Accountable Act of the United States (the “HFCAA”) on May 4, 2022.
-
The U.S. SEC continues to tighten the screws on Chinese companies, adding more than 80 companies to its expanding list of companies that might be dropped from U.S. stock exchanges.